Several classes of anti-obesity and anti-diabetes medications (such as metformin, 5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR), and PPARγ agonists) are known to modulate the immune system and result in improved insulin sensitivity. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.